Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Department of Internal Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
Published: October 2024
AI Article Synopsis
- Antibody-drug conjugates (ADCs) are a new type of targeted cancer treatment showing strong effectiveness across various cancers, particularly in non-small cell lung cancer (NSCLC).
- ADCs are now included in treatment options for some patients with metastatic NSCLC and are proving to be particularly useful in challenging cases involving central nervous system (CNS) metastases.
- The text reviews and summarizes current evidence on the performance of ADCs in NSCLC, emphasizing their potential impact on CNS metastasis treatment.
Article Abstract
Antibody-drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment armamentarium for a subset of patients with metastatic disease. Emerging data suggest that some ADCs exhibit impressive activity even in central nervous system (CNS) metastases, a disease site that is difficult to treat and associated with poor prognosis. Herein, we describe and summarize the existing evidence surrounding ADCs in NSCLC with a focus on CNS activity.
